

Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

Agilent: 2100 Bioanalyzer Instrument

RRID:SCR_018043

Type: Tool

Proper Citation

Agilent: 2100 Bioanalyzer Instrument (RRID:SCR_018043)

Resource Information

URL: <https://www.agilent.com/en/product/automated-electrophoresis/bioanalyzer-systems/bioanalyzer-instrument/2100-bioanalyzer-instrument-228250>

Proper Citation: Agilent: 2100 Bioanalyzer Instrument (RRID:SCR_018043)

Description: Bioanalyzer system is automated electrophoresis tool that provides an analytical evaluation of various samples types in many workflows, including next generation sequencing NGS, gene expression, biopharmaceutical, and gene editing research. Digital data is provided in timely manner and delivers assessment of sizing, quantitation, integrity and purity from DNA, RNA, and proteins. Minimal sample volumes are required for accurate result, and data may be exported in many different formats.

Synonyms: Agilent 2100 Bioanalyzer, , 2100 Bioanalyzer (Agilent Technologies)

Resource Type: instrument resource

Keywords: ABRF, bioanalyzer, electrophoresis, DNA, RNA, protein, data analysis, instrument, equipment

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018043.pdf

Resource Name: Agilent: 2100 Bioanalyzer Instrument

Resource ID: SCR_018043

Alternate IDs: SCR_019389, Model_Number_2100 Bioanalyzer

Alternate URLs:

https://www.agilent.com/cs/library/usermanuals/public/2100_Bioanalyzer_Expert_USR.pdf

Record Creation Time: 20220129T080338+0000

Record Last Update: 20260821T194128+0000

Ratings and Alerts

No rating or validation information has been found for Agilent: 2100 Bioanalyzer Instrument.

No alerts have been found for Agilent: 2100 Bioanalyzer Instrument.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 221 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sumii M, et al. (2026) Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. *Molecular cancer therapeutics*, 25(3), 435.

Barajas JM, et al. (2026) Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency. *Blood cancer discovery*, 7(1), 51.

Kelley RK, et al. (2026) T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(4), 694.

Maeda M, et al. (2026) CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1. *Molecular cancer*, 25(1).

Hajka D, et al. (2026) Bidirectional Communication Between Astrocytes and Neurons via Extracellular Vesicles: A Multi-Omics Approach. *Journal of neurochemistry*, 170(2), e70373.

Wang J, et al. (2026) Tumor-Resident *Streptococcus pneumoniae* Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. *Cancer research*, 86(9), 2237.

López-Fuentes E, et al. (2026) Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities. *Cancer discovery*, 16(2), 296.

Popov TM, et al. (2026) Two Molecular Subgroups Predict Most Recurrences in Advanced Laryngeal Squamous Cell Carcinoma. *Cancer research communications*, 6(1), 60.

Huang KK, et al. (2026) Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence. *Cancer discovery*, 16(3), 497.

Schlebusch SA, et al. (2026) Sex chromosome turnover and structural genome divergence shape meiotic outcomes in hybridizing *Cobitis*. *GigaScience*, 15.

Porschen LT, et al. (2026) Circulating sphingosine-1-phosphate depletion is associated with endothelial activation and altered brain-endothelial S1P pathway expression in ischemic stroke. *Fluids and barriers of the CNS*, 23(1).

Yousief SW, et al. (2026) Genome-wide identification of tissue-specific fitness genes in murine models of *Staphylococcus aureus* infection. *iScience*, 29(1), 114261.

Xu L, et al. (2026) Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFN γ -IRF1-SREBF2 Axis. *Cancer immunology research*, 14(3), 478.

Khan MA, et al. (2026) Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. *Cancer letters*, 638, 218160.

Huang W, et al. (2026) Core gastric microbiota linked to pathogenesis and preserved across age-stratified cohorts. *Cell reports. Medicine*, 7(7), 102905.

Shimada BK, et al. (2026) Global loss of selenocysteine lyase in mice drives lipid accumulation in brown adipocytes. *American journal of physiology. Endocrinology and metabolism*, 330(2), E000.

Belanger K, et al. (2026) Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. *Cancer research*, 86(14), 3604.

Skvir NJ, et al. (2026) High resolution spatial profiling of the hematopoietic landscape of the murine lung. *iScience*, 29(7), 116595.

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1434.

Suwalska A, et al. (2026) Mutational landscape of normal breast tissues adjacent to invasive breast cancer. *Cell reports. Medicine*, 102543.